Ono chases Takeda in polycythemia
Ono's antisense therapy is to begin its first pivotal trial.
Ono takes on Takeda in polycythemia vera
The Japanese group licenses sapablursen from Ionis for $280m.
FDA red and green lights: February 2025
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
The gist of GSK's move is to follow Ono
The UK company buys IRDx for $1bn.
Here comes another PD-1/VEGF bispecific
OncoC4’s AI-081 features among the industry’s latest first-in-human trial initiations.
